Peptides Lack Reliable Safety Information, Watchdog Warns Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Psoriasis harbors multiple pathogenic type 17 T cell subsets: Selective modulation by risankizumab Journal of Allergy and Clinical Immunology Real World Canadian Case Series: Use of Tildrakizumab for Moderate to Severe Psoriasis Inflammatory memory in psoriasis: From remission to recurrence Journal of Allergy and Clinical Immunology